StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Hold

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Thursday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a research note on Monday, September 9th.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ:ORMP opened at $2.48 on Thursday. The business’s 50 day simple moving average is $2.41 and its 200 day simple moving average is $2.45. Oramed Pharmaceuticals has a 1 year low of $1.67 and a 1 year high of $3.67. The company has a market capitalization of $100.76 million, a P/E ratio of 9.54 and a beta of 1.77.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.21. On average, sell-side analysts anticipate that Oramed Pharmaceuticals will post 0.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in shares of Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 10,774 shares in the last quarter. XTX Topco Ltd bought a new stake in Oramed Pharmaceuticals during the 2nd quarter worth approximately $40,000. Virtu Financial LLC acquired a new position in Oramed Pharmaceuticals in the 1st quarter valued at approximately $68,000. Renaissance Technologies LLC increased its position in Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after acquiring an additional 108,700 shares during the period. Finally, Murchinson Ltd. raised its stake in shares of Oramed Pharmaceuticals by 23.2% during the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock valued at $4,369,000 after acquiring an additional 320,495 shares during the last quarter. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.